Semaglutide vs. Tirzepatide in 2026: What the Latest Trial Data Shows
A head-to-head comparison of the two leading GLP-1 drugs based on STEP, SURMOUNT, SELECT, and SURPASS-5 trial data. Weight loss, cardiovascular outcomes, side effects, and what’s next in the pipeline.
Read Article →BPC-157: What the Science Actually Says (and What It Doesn’t)
An evidence-based review of BPC-157 research: the animal studies that generated excitement, the absence of human clinical trials, the FDA’s Category 2 classification, and what we actually know about safety.
Read Article →The Race for Oral Peptide Drugs: How Rybelsus Broke the Rules
Peptides were supposed to be impossible to take by mouth. Oral semaglutide (Rybelsus) disproved that with the SNAC absorption enhancer. Now orforglipron and others are attempting to go even further. Here’s the science.
Read Article →More articles coming soon. Browse the dictionary →